{
  "title": "Herold II ITN007AI:  Treatment with hOKT3-gamma-1 (Ala-Ala) in Type 1 Diabetes Mellitus",
  "identifier": {
    "identifier": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY569",
    "identifierSource": "http://www.immport.org"
  },
  "producedBy": {  "name": "Herold II ITN007AI:  Treatment with hOKT3-gamma-1 (Ala-Ala) in Type 1 Diabetes Mellitus",
  "performedBy": [
    {
      "firstName": "Kevan",
      "lastName": "Herold",
      "email": "kevan.herold@yale.edu",
      "affiliations": [
          {
             "name": "Yale University"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    }
  ],
  "studyGroups": [
        {
          "name": "hOKT3gamma1 (Ala-Ala) (teplizumab)",
          "size": 6
        },
        {
          "name": "Control",
          "size": 5
        }
  ],
  
  "selectionCriteria": [
        {
          "category": "Inclusion",
          "values": [
              "Diagnosed with type 1 diabetes within the past 6 months"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Have a body weight greater than or equal to 26 kg at the time of enrollment"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Have detectable anti-GAD, anti-ICA512 IA-2, or insulin autoantibodies (fi the participant has been on insulin less than or equal to 10 days"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Pregnant or lactating females"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Prior OKT3 treatment"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Known hypersensitivity to murine products"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Uncompensated heart failure or fluid overload, recent myocardial infarction"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "History of epilepsy, cancer, active infection, atopic disease, active Grave's disease, cystic fibrosis, sickel cell anemia, neuropathy, peripheral vascular disease, cerebrovascular disease, any concurrent autoimmune diseases, asthma"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Inability to give informed consent"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Prior participation in a clinical trial that could potentially affect diabetes or immunologic status"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Participation in a clinical trial within the last 6 weeks"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "HIV positive"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Positive for hepatitis B surface antigen or anti-hepatitis C antibody"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Seropositivity for Toxoplasmosis (IgG)"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Lymphopenia less than 1000 lymphocytes per microliter"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Thrombocytopenia less than 150,000 per mL cubed platelets"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Anemia Hgb less than 10g per dL"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Vaccination with a live virus within the past 6 weeks"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Positive for PPD skin test"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Any infectious mononucleosis-like illness within the 3 months prior to enrollment"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Serologic evidence of acute infection with EBV or CMV"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Any medical condition that in the opinion of the investigator wil interfere with safe completion of the trial"
          ]
        }
  ],
  
  "types": [
      {
          "value": "Intervention Longitudinal"
      }
  ]
  },
  "creators": [
    {
      "firstName": "Kevan",
      "lastName": "Herold",
      "email": "kevan.herold@yale.edu",
      "affiliations": [
          {
             "name": "Yale University"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    },
    {
      "name": "Immune Tolerance Network",
      "extraProperties": [
        {
          "category": "Catgory",
          "values": [
            {
              "value": "DAIT"
            }
          ]
        },
        {
          "category": "External Id",
          "values": [
            {
              "value": "N/A1"
            }
          ]
        },
        {
          "category": "Description",
          "values": [
            {
              "value": "Immune Tolerance Network"
            }
          ]
        }
      ]
    }
  ],
  "types": [
      {
        "value": "Clinical Trial"
      },
      {
        "value": "Intervention Longitudinal"
      },
      {
        "value": "Autoimmune"
      }
  ],
  "dates": [
      {
          "date": "2002-05-01",
          "type": {
              "value": "actual_start_date"
          }
      },
      {
          "date": "2016-06-17",
          "type": {
              "value": "final_public_release_date"
          }
      }
  ],
  "availability": "Available for download after registration with ImmPort",
  "refinement": "Curated",
  "dimensions": [{
        "name": {
            "value": "Comprehensive Metabolic Panel"
        }
      },{
        "name": {
            "value": "Blood Cell Count with Differential"
        }
      },{
        "name": {
            "value": "Protein or Enzyme Type Measurement"
        }
      },{
        "name": {
            "value": "Mixed-Meal Tolerance Test"
        }
      },{
        "name": {
            "value": "Urinalysis"
        }
      },{
        "name": {
            "value": "Immunology Test"
        }
      }
      
  ],
  
  "distributions": [
      {
          "identifier": {
              "identifier": "SDY569",
              "identifierSource": "ImmPort"
          },
          "title": "Herold II ITN007AI:  Treatment with hOKT3-gamma-1 (Ala-Ala) in Type 1 Diabetes Mellitus",
          "access": {
              "landingPage": "http://www.immport.org",
              "accessURL": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY569",
              "types": [
                  {
                      "value": "Download tab separated files"
                  },
                  {
                      "value": "Download MySQL files and schema"
                  }
              ],
              "authorizations": [
                {
                    "value": "Registraton with ImmPort required"
                }
              ]
          },
          "storedIn": {
              "name": "ImmPort",
              "types": [
                {
                  "value": "primary repository"
                }
              ]
         },
         "licenses": [
           {
             "name": "ImmPort User Agreement",
             "version": "1.0",
             "extraProperties": [
               {
                 "category": "Link to User Agreement",
                 "values": [
                   {
                     "value": "http://www.immport.org/agreement"
                   }
                 ]
               }
             ]
           }
         ]
      }
  ],
  "acknowledges": [
    {
      "identifier": {
        "identifier": ""
      },
      "name": "Immune Tolerance Network",
      "extraProperties": [
        {
          "category": "Link",
          "values": [
            {
              "value": "https://www.fpds.gov/ezsearch/search.do?s=FPDS&q=%22IT+strategy%22+OR+%22enterprise+architecture%22+DEPARTMENT_FULL_NAME%3A%22HEALTH+AND+HUMAN+SERVICES%2C+DEPARTMENT+OF%22+PIID%3A%22HHSD2002011F41972%22+VENDOR_ADDRESS_ZIP_CODE%3A%22221027508%22+GLOBAL_VENDOR_NAME%3A%22GAVER+TECHNOLOGIES++INC.%22+VENDOR_FULL_NAME%3A%22VANGENT%2C+INC.%22+TREASURY_ACCOUNT_SYMBOL%3A%22750885%22+CONTRACTING_OFFICE_NAME%3A%22NIH%2C+NIAID+DEA+OA+OFC+ACQUISITIONS%22+VENDOR_FULL_NAME%3A%22ST.+LOUIS+UNIVERSITY%22+PRODUCT_OR_SERVICE_CODE%3A%22AB93%22+PRINCIPAL_NAICS_CODE%3A%22325414%22+VENDOR_ADDRESS_ZIP_CODE%3A%22277088990%22+PIID%3A%22HHSN266200500019C%22&indexName=awardfull&templateName=1.4.4"
            }
          ]
        }
      ]}
  ],
  "licenses": [
    {
      "name": "ImmPort User Agreement",
      "version": "1.0",
      "extraProperties": [
        {
          "category": "Link to User Agreement",
          "values": [
            {
              "value": "http://www.immport.org/agreement"
            }
          ]
        }
      ]
    }
  ],
  "description": "This is a phase II study examining clinical and immunological effects of humanized FcR non-binding anti-CD3 mAb in participants with Type 1 diabetes mellitus (T1DM), and to develop this therapy to prevent immune destruction leading to beta cell loss."
}
